||The Author(s) 2016. This article is published with open access a www.chitkara.edu.in/publications
The area of pharmaceutical research is broadened with the invention of new pharmaceutical drug delivery system. The traditional drug deliveries systems have not the way to treat or cure special disease or as well as the common disease with less side effects and maximized efficacy. ODDS have various advantages and disadvantages but their disadvantages are overcome by the CDDS. CDDS although they overcome the disadvantages of ODDS but do not handle the special pharmacological disease requirements. To overcome this PDDS is established to overcome the disadvantages of CDDS. PDDS has gained importance in the drug delivery system because of improved patient compliance, therapeutic efficacy and having fewer side effects. PDDS uses lag time for delivery of drug in body. Various systems are there in PDDS to overcome the patient’s special chronopharmacological needs.
||Print : 2321-2217, Online : 2321-2225
- Auvil-Novak SE. The chronobiology, chronopharmacology, and chronotherapeutics of pain. Annu Rev Nurs Res. 1999; 17: 133–153.
- Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically Driven Delivery Devices with Pulsatile Effect. US Patent No. 5209746; 1993.
- Bodmeier R, Guo X, Sarabia RE, Skultety P. The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Pharm Res 1996; 13(1): 52–56. http://dx.doi.org/10.1023/A:1016021115481
- Chen CM. Multiparticulate Pulsatile Drug Delivery System. US Patent No. 5, 508,040; 1996.
- Janugade B. U.1*, Patil S. S., Patil S. V.1, Lade P. D. Formulatiom and evaluation of press coated montelukast sodium tablet. International Journal of Chemtech Research. 2009.
- Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. J Pharm Sci 1996; 85(2):184–188. http://dx.doi.org/10.1021/js950180o
- Nitin S, Satarkar, Zach Hilt S. Magnetic hydrogel nanocomposite for remote controlled pulsatile drug release. J Cont Relea 2008;130:246–251. http://dx.doi.org/10.1016/j.jconrel.2008.06.008
- Pulsatile drug delivery release technology: An overview Suresh Rewar*, Bansal B.K., Singh C.J., Sharma A.K. 2015.
- Patel PK, Patel C K, “Pulsatile Drug Delivery System”, AJPSCR 2012; 1: 44–51.
- Rajput Meenu, Sharma Ritika, Kumar Sunil, Pulsatile Drug Delivery: A review. International Journal of Pharmaceutical Research and Biomedical Sciences. ISSN :2229–3701.
- Rigas AN, Bittles AH, Hadden DR, Montgomery DA. Circadian variation of glucose, insulin, and free fatty acids during long-term use of oral hypoglycaemic agents in diabetes mellitus. Br Med J 1968; 3: 25– 28. http://dx.doi.org/10.1136/bmj.4.5622.25
- Santini JT, Cima MJ, Langer R. A controlled-release microchip. Nature 1999; 335–338.
- Sarawade A, Ratnaparkhi M.P., Chaudhri S., “Floating drug delivery system: An Overview”, Int. J. Res. Dev.